4.5 Article

Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center

期刊

NUTRITION
卷 32, 期 4, 页码 418-425

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.nut.2015.08.025

关键词

Pediatrics; Crohn's disease; Ulcerative colitis; Inflammatory bowel disease; IBD; Nutritional therapy; Dietary therapy; Complementary and alternative medicine; CAM; Low complex carbohydrate; Specific carbohydrate diet

向作者/读者索取更多资源

Objective: Despite dietary factors being implicated in the pathogenesis of inflammatory bowel disease (IBD), nutritional therapy, outside of exclusive enteral nutrition (EEN), has not had a defined role within the treatment paradigm of pediatric IBD within IBD centers. Based on emerging data, Seattle Children's Hospital IBD Center has developed an integrated dietary program incorporating the specific carbohydrate diet (SCD) into its treatment paradigm. This treatment paradigm uses the SCD as primary therapy as well as adjunctive therapy for the treatment of IBD. The aim of this study was to evaluate the potential effects of the SCD on clinical outcomes and laboratory studies of pediatric patients with Crohn's disease (CD) and ulcerative colitis (UC). Methods: In this retrospective study, we reviewed the medical records of patients with IBD on SCD. Results: We analyzed 26 children on the SCD: 20 with CD and 6 with UC. Duration of the dietary therapy ranged from 3 to 48 mo. In patients with active CD (Pediatric Crohn's Disease activity index [PCDAI] >10), PCDAI dropped from 32.8 +/- 13.2 at baseline to 20.8 +/- 16.6 by 4 +/- 2 wk, and to 8.8 +/- 8.5 by 6 mo. The mean Pediatric Ulcerative Colitis Activity Index for patients with active UC decreased from a baseline of 28.3 +/- 10.3 to 20.0 +/- 17.3 at 4 +/- 2 wk, to 18.3 +/- 31.7 at 6 mo. Conclusion: This retrospective review provides evidence that the SCD can be integrated into a tertiary care center and may improve clinical and laboratory parameters for pediatric patients with nonstructuring, nonpenetrating CD as well as UC. Further prospective studies are needed to fully assess the safety and efficacy of the SCD in pediatric patients with IBD. (C) 2016 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据